Explore the words cloud of the PRO-CF-MED project. It provides you a very rough idea of what is the project "PRO-CF-MED" about.
The following table provides information about the project.
PROQR THERAPEUTICS NV
|Coordinator Country||Netherlands [NL]|
|Total cost||21˙237˙179 €|
|EC max contribution||5˙997˙139 € (28%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2015-05-01 to 2017-12-31|
Take a look of project's partnership.
|1||PROQR THERAPEUTICS NV||NL (LEIDEN)||coordinator||4˙453˙544.00|
|2||UNIVERSITE CATHOLIQUE DE LOUVAIN||BE (LOUVAIN LA NEUVE)||participant||394˙612.00|
|3||INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE||FR (PARIS)||participant||359˙927.00|
|4||PATERGRUS BVBA||BE (AALTER)||participant||330˙085.00|
|5||EUROPEAN CYSTIC FIBROSIS SOCIETY||DK (KARUP)||participant||230˙720.00|
|6||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||participant||228˙250.00|
Cystic fibrosis (CF) is a progressive life-shortening disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene leading to a dysfunctional CFTR protein. The disease affects over 70,000 patients worldwide and while many mutations are known, the F508del mutation affects 90% of all patients. The absence of CFTR in the plasma membrane leads to a dramatic decrease in chloride efflux, resulting in viscous mucus that causes severe symptoms in vital organs like the lungs and intestines. For CF patients that suffer from the life threatening F508del mutation only palliative treatment exist.
PRO-CF-MED addresses the specific challenge of this call by introducing the first disease modifying medication for the treatment of the CF patients with F508del mutation. The PRO-CF-MED project has been designed to assess the potential clinical efficacy of QR-010, an innovative disease modifying oligonucleotide-based treatment for F508del patients.
Partners within PRO-CF-MED have generated very promising preclinical evidence for QR-010 which allows for further clinical assessment of QR-010 in clinical trials. PRO-CF-MED will enable the fast translation of QR-010 towards clinical practice and market authorisation. PRO-CF-MED has the potential to transform this life-threatening condition into a manageable one.
|PRO-CF-MED project website developed including project updates and patient â€˜friendlyâ€™ section||Websites, patent fillings, videos etc.||2019-03-22 17:18:45|
Take a look to the deliverables list in detail: detailed list of PRO-CF-MED deliverables.
|year||authors and title||journal||last update|
I Sermet-Gaudelus, D Nichols, JA Nick, C De Boeck, JP Clancy, GM Solomon, SM Rowe, JS Elborn, MA MAll, JA Bolognese, F Bouisset, W den Hollander, N Lamontagne, N Tomkinson, N Henig
QR-010 significantly improves CFTR function in nasal potential difference proof of concept study in subjects with CF homozygous for the F508del-CFTR mutation
published pages: , ISSN: , DOI:
Sabrina Noel, Bela Z Schmidt, Jeremy Haaf, Teresinha Leal
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
published pages: 127-140, ISSN: 1179-1438, DOI: 10.2147/CPAA.S100759
|Clinical Pharmacology: Advances and Applications Volume 8||2019-05-24|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRO-CF-MED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PRO-CF-MED" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Global Alliance for Chronic Diseases SecretariatRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More